ARDX — Q2 2026 Financial Report Analysis

IBSRELA carries a 31% jump in product sales, but the narrower loss owes more to a lapsed royalty than to operations

Ardelyx sells two drugs, both made from the same molecule, tenapanor. IBSRELA treats irritable bowel syndrome with constipation (IBS-C). XPHOZAH lowers blood phosphorus in kidney-failure patients on dialysis. In the second quarter of 2026 the two together brought in $118.1 million of net product sales, up 31% from $90.1 million a year earlier. Total revenue, which also includes small amounts of partner supply and royalty income, rose 24% to $120.9 million. The net loss narrowed to $16.7 million ($0.07 per share) from $19.1 million ($0.08). Most of that improvement comes from a royalty payment to AstraZeneca that ended in mid-2025. Without it, the operating loss widened slightly, because the company is spending more on a late-stage trial that could expand IBSRELA's market.

At a glance

• IBSRELA net sales: $86.2 million, up 33% year on year and 23% on Q1. It now accounts for 73% of product sales and is the company's growth engine. The 10-Q credits "higher demand, driven by continued increase in awareness and prescriber experience, and to a lesser extent, higher net price."
• Gross-to-net deduction: 34.0% of gross sales, up from 31.3%. Gross-to-net means the share of list-price sales given back as rebates, discounts and patient copay support. Ardelyx is keeping a smaller slice of each list-price dollar than it did a year ago.
• Cash and investments: $281.8 million against $250.0 million of term debt. That cushion includes a $50 million loan drawn on June 29. Operating cash burn for the first half was $38.6 million.

The numbers

Operating margin is operating profit or loss as a share of revenue; here it is negative because the company still spends more than it earns. "n/m" means a percentage change isn't meaningful when comparing one loss with another.

IBSRELA: where the growth is

IBSRELA grew $21.2 million year on year. For the first half it reached $156.3 million, up 43%. Compared with Q1 2026 ($70.1 million, derived from the six-month total), it grew 23% in a single quarter. Some of that rebound is seasonal: first quarters tend to be weak for US branded drugs because insurance deductibles reset in January. Even so, the year-on-year rate shows demand is still building. Management attributes the growth mainly to more prescriptions, with price playing a smaller role.

Ardelyx is spending to keep that going. SG&A (selling, general and administrative costs) rose $17.5 million to $101.4 million. The 10-Q says the increase "primarily reflected increased commercialization and administrative costs to support net sales growth of IBSRELA." That covers disease-awareness campaigns, patient affordability and access support, extra headcount, and $3.1 million more in stock-based pay. SG&A now equals 84% of total revenue, so profitability depends on sales growing faster than this spending.

The other lever is R&D, up 67% to $26.1 million. External R&D costs more than doubled to $13.9 million, and more than half went to the Phase 3 ACCEL trial. ACCEL tests tenapanor in chronic idiopathic constipation (CIC), a larger condition that IBSRELA isn't yet approved for. The first patient was dosed in January 2026. Ardelyx expects to finish enrollment by the end of 2026 and report topline data in the second half of 2027.

XPHOZAH: growing, but against a reimbursement headwind

XPHOZAH sales rose 27% to $31.9 million. The 10-Q attributes this to "higher demand and net price." The comparison is easy, though. In January 2025, Medicare moved XPHOZAH out of Part D (pharmacy coverage) and into the bundled per-treatment payment that dialysis clinics receive (the ESRD PPS). After that change, clinics absorb the drug's cost themselves. The 10-Q says this "had a negative and material impact on our XPHOZAH revenue in 2025."

Two developments this year make a reversal less likely:

• On March 27, 2026, CMS issued guidance that dialysis facilities are expected to supply XPHOZAH under the bundled payment "regardless of manufacturer distribution preferences." The company warns this "may limit our ability to effectively pursue alternative distribution approaches."
• On June 26, 2026, an appeals court affirmed the dismissal of Ardelyx's lawsuit against CMS over the bundling. The company says it is not pursuing further litigation.

So XPHOZAH's path now runs through the bundle, with no legal route left to change it. For the first half, XPHOZAH grew only 14% ($55.2 million vs $48.4 million). But H1 2025 included a one-time $3.8 million favorable adjustment to estimated product returns. Without it, first-half growth would be about 24%.

What the headline numbers hide

• The loss narrowed mostly because a royalty ended, not because operations improved. Cost of sales fell from $12.4 million to $5.8 million. Of that drop, $3.8 million is the AstraZeneca royalty: Ardelyx had been paying it from product revenue under its termination agreement with AstraZeneca, up to a $75 million cap. The cap was reached at the end of Q2 2025. Removing that $3.8 million from last year's costs puts Q2 2025's operating loss at about $10.6 million, compared with $12.4 million this quarter. On that like-for-like basis, the operating loss widened by roughly $1.8 million. The reason is the jump in R&D spending on ACCEL, which is a deliberate choice, not a sign of a weak quarter.
• Gross-to-net is moving the wrong way. Deductions rose 48% while gross sales rose 36%. The 10-Q blames "an unfavorable channel mix as well as Medicare and Medicaid Inflation Rebate charges." Inflation rebates are penalties drug makers pay the government when they raise prices faster than inflation. In other words, part of Ardelyx's list-price gains is being returned in rebates. The ratio did improve from Q1 2026's 36.3% (derived from the six-month figures), so the trend is volatile rather than steadily worsening.
• Stock-based pay is most of the loss. Stock-based compensation was $15.3 million in the quarter, against a $16.7 million net loss. This is a real cost to shareholders because it dilutes them: diluted share count rose 3.4% year on year to 248.1 million. But it doesn't use cash.
• Cash burn improved for timing reasons as much as operating ones. First-half operating cash outflow fell to $38.6 million from $63.8 million. The 10-Q attributes this mainly to "the timing of our payments and inventory purchases." Accounts payable and accrued liabilities together provided about $41.6 million of cash in the half. Receivables used $28.5 million: money owed by customers rose 40% in six months to $100.4 million. When the payables are paid, part of the improvement will reverse.
• Partner revenue shrank, and part of it is non-cash. Product supply revenue from partners fell to $2.0 million from $6.2 million, because shipments shifted from Kyowa Kirin to Fosun Pharma. The $0.7 million of royalty revenue from PHOZEVEL in Japan is passed straight through to HealthCare Royalty (HCR) to repay an earlier financing, so Ardelyx doesn't keep that cash.

Takeaway: IBSRELA is growing fast enough (up 33% year on year to $86.2 million) to absorb rising sales costs and a doubling of external R&D. But the narrower headline loss mostly reflects a $3.8 million AstraZeneca royalty that no longer applies. Underlying operating losses were about flat to slightly wider, and gross-to-net deductions are taking a bigger slice of every sale.

Balance sheet and refinancing

In April, Ardelyx signed a sixth amendment to its loan agreement with SLR. It cut the interest rate on all term loans to 4.55% plus the greater of one-month SOFR or 3.50%. It also extended the maturity of all tranches to July 1, 2030, interest-only until then. The amendment cost about $1.9 million in fees and prepayment premium. On June 29 the company drew the $50 million Term F loan "for general corporate purposes," bringing debt to $250.0 million. Repayment, including final fees, totals $260.8 million in 2030. A further $50 million (Term G) can be drawn until December 20, 2026. A $100 million at-the-market stock program, which lets the company sell shares gradually on the open market, hasn't been used.

Excluding the new $50 million loan, cash and investments would have dropped from $264.7 million at year-end to about $232 million. That reflects the roughly $38 million first-half operating burn. Management says current funds will cover "planned operations for at least a period of one year." The 10-Q also says the company expects to "increasingly rely on cash generated from our commercial operations."

Outlook

The 10-Q gives no revenue guidance. Our read: the quarter supports the view that Ardelyx's path to breakeven depends almost entirely on IBSRELA. Q2's operating loss was $12.4 million, including $15.3 million of stock-based compensation, so operations before stock-based pay were already about $2.9 million in the black. If IBSRELA keeps growing near its 30%+ year-on-year rate while SG&A grows around 20%, reported operating breakeven looks reachable without new money. The open question is how much R&D rises as ACCEL enrolls.

Three things to watch:

1. Gross-to-net: whether it settles around the Q2 level of 34% or climbs back toward Q1's 36%. Every point is worth about $1.8 million of quarterly net sales at current gross volume.
2. XPHOZAH under the bundle: whether it keeps growing with no legal route left, now that CMS has reiterated that clinics must supply it under the bundled payment.
3. R&D and cash: ACCEL enrollment is due to finish by year-end, with data in the second half of 2027. If the trial succeeds, IBSRELA's addressable market expands. Until then, R&D will keep running well above last year's level. The undrawn $50 million Term G loan and the unused share program are the backstops if cash generation lags.